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Abstract
Background: Tuberculosis is a major public health problem in Ethiopia, and a high number of TB patients are
co-infected with HIV. There is a need for more knowledge about factors influencing treatment adherence in
co-infected patients on concomitant treatment. The aim of the present study is to explore patients’ and health
care professionals’ views about barriers and facilitators to TB treatment adherence in TB/HIV co-infected patients on
concomitant treatment for TB and HIV.
Methods: Qualitative study using in-depth interviews with 15 TB/HIV co-infected patients and 9 health
professionals and focus group discussions with 14 co-infected patients.
Results: We found that interplay of factors is involved in the decision making about medication intake. Factors
that influenced adherence to TB treatment positively were beliefs in the curability of TB, beliefs in the severity of
TB in the presence of HIV infection and support from families and health professionals. Barriers to treatment
adherence were experiencing side effects, pill burden, economic constraints, lack of food, stigma with lack of
disclosure, and lack of adequate communication with health professionals.
Conclusion: Health professionals and policy makers should be aware of factors influencing TB treatment in TB/HIV
co-infected patients on concomitant treatment for TB and HIV. Our results suggest that provision of food and
minimal financial support might facilitate adherence. Counseling might also facilitate adherence, in particular for
those who start ART in the early phases of TB treatment, and beliefs related to side-effects and pill burden should
be addressed. Information to the public may reduce TB and HIV related stigma.
Background
Tuberculosis is a major public health problem in Ethio-
pia, with an estimated incidence of 379 per 100 000 and
a prevalence of 643 per 100 000 [1]. According to hospi-
tal statistics data, TB is the leading cause of morbidity,
the third cause of hospital admission and the second
cause of death in Ethiopia [2]. There is a high rate of
HIV among patients with TB in Ethiopia. The WHO
Global Report 2008 estimated that 40% of patients trea-
ted for TB are HIV positive [2].
Effective treatment exists for both TB and HIV. Evi-
dence shows that ART treatment can have a significant
impact on the HIV and TB related morbidity and
mortality in co-infected patients; but concomitant treat-
ment is complicated by factors such as overlapping drug
toxicities, drug-drug interactions and possible paradoxi-
cal reactions [3-7]. Concomitant treatment also leads to
a higher pill burden. There is an association between
poor adherence and the pill burden associated with a
regimen, the regimen’s complexity, and the extent to
which the regimen impacts on the patient’s daily life
[8-11]. Co-infected patients on concomitant treatment
may thus be at risk for decreased adherence to either or
both treatments. Low adherence to TB treatment can
lead to an increased risk of drug resistance, relapse,
death, and may prolong infectiousness [12].
Adherence is defined by WHO as “the extent to which a
person’s behavior- taking medication, following a diet, and
or executing lifestyle changes, corresponds with agreed
recommendations from a health care provider” [13].
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Adherence it is a concept that allows for a comprehensive
assessment of factors related to medication intake such as
characteristics of the regimen; attitudes of the providers;
socio-economic, cultural and environmental factors
[14,15].
Studies of patients’ adherence to TB treatment in
Ethiopia have identified socio-economic and structural
barriers to adherence, including lack of money to pay
for transportation, high distance from clinics, the diffi-
culties associated with daily treatment and rigid routines
at health facilities [12,16-23]. Inadequate knowledge
about the illness was also found to adversely impact
adherence. The studies also showed that family support,
involvement in TB clubs, and adequate knowledge about
the disease were facilitators of TB treatment adherence
[12,16-23].
To our knowledge, no study has explored the experi-
ences of TB/HIV co-infected patients receiving concomi-
tant treatment in Ethiopia. How concomitant treatment
affects TB treatment adherence has similarly not been
explored. A review of qualitative studies of factors con-
sidered as important by patients, caregivers and health
care providers for TB medication adherence indicated a
lack of evidence on the experiences of patients living
with HIV/AIDS and taking treatment for TB or for both
illnesses [11]. There is a need for more knowledge about
factors influencing treatment adherence in co-infected
patients on concomitant treatment. We thus conducted a
study to explore patients’ and health care professionals’
views about barriers and facilitators to TB treatment
adherence in co-infected patients who received concomi-
tant treatment for TB and HIV.
Methods
Setting
The study was conducted in Addis-Ababa, the capital
city of Ethiopia, in the period July 2008 to October
2008. The health service coverage in Addis-Ababa, with
regards to geographical accessibility, is 100% [24]. Out-
patient TB treatment is mainly provided by governmen-
tal health centers. These health centers are administered
by the Addis Ababa Health Bureau and provide medical
services for the populations within their catchments
areas. TB clinics have been operating for many years in
local health centers, and ART clinics were established in
2006, as part of the expansion of HAART provision pro-
gram initially started in hospitals [25]. The health cen-
ters offer free ART service and care for patients with
HIV infection. In addition to diagnosis and treatment of
patients with TB, the TB clinics also offer the Provider
Induced Counseling and Treatment (PICT) service
through which all patients coming to the TB clinics are
offered screening for HIV. Both TB and ART treatments
are offered free of charge in these health centers.
The different health centers in general do not have sig-
nificant differences in terms of services they provide and
in terms of health personnel and equipments available.
Participants
We collected data using in-depth interviews and focus
group discussions. We conducted individual interviews
with 15 patients (7 men, 8 women) who had been on
concomitant treatment for TB and HIV, and we inter-
viewed nine health professionals (6 clinical nurses,
2 health officers and 1 doctor) who were involved in the
treatment of these patients. We conducted a preliminary
analysis of our in-depth interviews, identifying major
themes emerging from our data. We subsequently con-
ducted two focus group discussions with a total of
14 patients (7 men, 7 women), in order to further
explore and validate our preliminary findings from the
in-depth interviews. Participants were recruited from
three out of 21 health centres: Bole Health Center,
Arada Health Center and Woreda 7 Health Center.
We used a maximum variation sampling strategy
when recruiting participants, to ensure diversity in views
and experiences. We thus included participants with
diversity with regards to age, gender, education, and
occupation. In addition, we included patients for whom
ART was started at different stages during TB treatment
(before anti-TB initiation, in intensive phase, in conti-
nuation phase). We ensured diversity of treatment
experiences by interviewing an equal number of patients
who had defaulted treatment and with successful treat-
ment; we also included three patients who were on
retreatment.
Patients with pre-specified characteristics were invited
to participate in the study through an invitation
letter provided by health personnel. Patients who had
defaulted treatment were contacted by health personnel
on our behalf while being traced after treatment discon-
tinuation at the TB clinics and two were contacted
through personnel at the ART clinic. Only one patient
declined to participate in the study. Health personnel
were directly invited by the first author (MK) to partici-
pate in the study. We interviewed patients who had
either completed or discontinued treatment in the past
six months before data collection.
Data collection
Audio-recorded individual interviews and focus group
discussions were conducted by MK in Amharic. Indivi-
dual interviews took place in private rooms, and a semi-
structured format with open-ended questions was used.
The questions covered participants’ perceptions about
TB, HIV and co-infection; experiences of concomitant
medication intake; factors positively and adversely influ-
encing TB medication intake while on concomitant
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ART treatment; and experiences at both TB and HIV
clinics. Similar topics were covered in the focus group
discussions, and issues that arose in the interviews were
brought up for further discussion. We used this triangu-
lation of data sources in order to increase the validity of
findings in our study.
We developed a semi-structured interview guide for
patients that was inspired by a theoretical framework for
health related behaviors, in which the following six
major categories are essential: accessibility of health
care; evaluation of health care; perception of symptoms
and threat of disease; social network characteristics;
knowledge about disease; demographic characteristics
[26]. The interview guide was also inspired by further
review of literature on adherence which indicates the
importance of other factors such as regimen related fac-
tors and health service related factors [8-11,27].
We developed an interview guide for health workers,
and we explored their experiences with adherence to
treatment in co-infected patients on concomitant treat-
ment, with a focus on barriers and facilitators to adher-
ence. Other questions such as what they do to try and
assist patients with adherence, what they would recom-
mend would assist patients with their medication intake
were also included.
Data analysis
Audio-recorded data from interviews of patients was
transcribed verbatim and translated into English. A pre-
liminary analysis of interviews was done, and used for
validation of results and further exploration using focus
group interviews. Data from health worker interviews
and focus group discussions which were also audio-
recorded were also transcribed verbatim and translated
into English.
The final analysis involved identification and coding of
material about participants’ perceptions about TB and
HIV, perceived barriers and facilitators of TB treatment
adherence using Giorgi’s phenomenological method, as
modified by Malterud [28]. MK read the material to get
an overview and subsequently identified units of mean-
ing that represent different aspects of participants’ per-
ceived barriers and facilitators to adherence. MK and
the third author (JCF) agreed on a list of codes and then
MK coded the material. All authors participated in con-
densing and summarizing the content of each code in
order to make generalized descriptions concerning bar-
riers and facilitators to TB treatment.
Ethics
Informed consent was obtained from all participants
prior to data collection. Anonymity and confidentiality
were ensured. The study has been approved by the
Regional Committees for Medical and Health Research
Ethics (REK) in Norway and was granted ethical clear-
ance by Addis Ababa Health Bureau in Ethiopia.
Results
We found that interplay of factors is involved in the
decision making about medication intake. Factors that
influenced adherence to TB treatment positively were
beliefs in the curability of TB, and in the severity of TB
in the presence of HIV infection, support from families
and health professionals. Barriers to treatment adher-
ence were experiencing side effects, pill burden, eco-
nomic constraints, stigma with lack of disclosure, and
lack of adequate communication with health profes-
sionals. Table 1 presents a summary of study findings
and their relationship to categories from our theoretical
framework.
Beliefs about TB, TB treatment and co-infection
A majority of patients explained that TB could be cured,
despite the presence of a concomitant HIV infection;
but many also thought that it was more difficult to be
cured when one had HIV. “Weakening” of the body by
HIV was mentioned by one group of participants who
explained that the two diseases “support each other” to
weaken the body.
“If you have HIV, TB can be strong, because they can
collide. If you do not have HIV, TB will disappear soon.
Like any person who has TB, you take your drug, and it
disappears, but if you have HIV, it will not disappear
fast.” (20 year-old female participant)
This in turn was mentioned by patients as being a rea-
son to take TB medications properly when one was
infected with HIV. A woman explained:
“You have to take what the doctors give you, you can
not stop that. You can only live if you take the drugs.
Two diseases, it will kill you at once, your body can not
support that. We are different from those who have TB
only.” (50 year-old female participant)
Health professionals underlined the presence of this
belief among patients, and said that many patients co-
infected with TB and HIV are motivated to take their
TB treatment properly because of the fear of getting
severe TB symptoms because of the HIV.
There were divergent views among patients about
which disease they thought was the most severe when
comparing TB and HIV. One group mentioned HIV as
being the most serious illness that they feared more,
while another group thought that TB was more danger-
ous. Patients’ views about severity affected the decision
about which drugs to discontinue for those patients who
decided to take one of the drugs and stop the other. A
36 years old male defaulter explained the reason why he
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decided to discontinue his anti-TB drugs and continue
with the ART after experiencing side effects aggravated
by lack of food:
“I have to take at least one of the drugs. I wanted to
survive. I said, I will take the HIV drugs only. Inter-
viewer: Why the HIV drugs and not the TB drugs? The
HIV, it will kill you, it will kill you fast. Samba (TB) will
not kill me if I take these drugs (ARV drugs) properly.”
(36 year-old male participant)
A factor that most health professionals believed helped
patients to gain hope was the improvement they
observed in other patients who had previously been cri-
tically ill. According to health professionals, that helped
patients believe in the efficacy of treatment and hence
gave them hope for themselves. A medical doctor stated:
“I think many patients are encouraged to come because
they see critically ill patients with co-infection who have
improved. That gives them a lot of hope.” (medical
doctor)
Pill burden and side effects
Patients mentioned pill burden as being one of the
major challenges of concomitant treatment, and they
used expressions such as “becoming a drug bag”, and
“becoming a pharmacy”. In addition to anti-TB drugs
and ARV drugs, patients were also taking co-trimoxa-
zole for PCP prophylaxis; and some in addition had to
take drugs for other illnesses. From the perspective of
some patients, a high number of pills was associated
with potential damage to the body and a higher risk of
not tolerating the drugs.
“Swallowing so many drugs, it was very difficult. I was
scared that it would harm my body. Drugs can harm
you if they are too many.” (36-year-old male participant)
This belief was reinforced by some health profes-
sionals, as noted by a medical doctor:
“When they think about pill burden, they say, can I
tolerate this, won’t this kill me? Taking many pills is per-
ceived as lethal by some. Patients worry a lot about
whether their body will be able to handle so many pills
every day.” (medical doctor)
Forgetfulness and mix up of drugs as a result of high
pill burden were also reported by some patients.
Side effects were experienced by more than half of the
participants, mainly at the beginning of anti-TB treat-
ment or upon initiation of concomitant treatment.
Among side effects patients mentioned were generalized
body weakness, burning of the stomach, “turning of
the head”, headache, bad dreams, rash and vomiting.
A 57 year-old male participant who discontinued both
his anti-TB and ART treatment after experiencing
severe side effects explains:
“I continued the drugs but the nightmares and the
hunger became too much. And then, I don’t really even
know how, my mind was also disturbed, so I took the
drugs for some time, and stopped all drugs. You know
the nightmare! And since I had no one beside me, and
since the medications were disturbing me at night,
and since it was pushing me to run away, I got scared
and stopped the drugs.” (57 year-old male participant)
Lack of food
The majority of patients believed that lack of food or
intake of inadequate food was associated with more
severe side effects and a difficulty to tolerate the drugs.
The amount and quality of food needed and the degree
of possible side effects were also believed by some
patients to be proportional to the drugs taken. Lack of
food was mentioned as a factor adversely affecting their
treatment by those patients who had insufficient
income. Patients mentioned drugs could be harmful on
an empty stomach, and that it was better not to take
drugs if one had not eaten. Health professionals recog-
nized the problem of food as being common, especially
with the gain in appetite related to improvement.
A clinical nurse explained:
“That (food) is a very serious problem for many of our
patients. They almost want to kill us wanting help. They
come here asking for help from NGOs. They say that
especially TB drugs increase appetite. They feel hungry
after they start feeling well a bit, and food becomes a
problem.” (nurse)
Table 1 Relationship between study findings and categories from theoretical framework
Theoretical framework Related study findings
Accessibility of health care Challenges of DOT
Evaluation of health care Interaction with health personnel
Perception of symptoms and threat of disease Beliefs about TB, TB treatment and co-infection
Social network characteristics Social support, Stigma
Knowledge about disease Beliefs about TB and co-infection
Demographic characteristics (social status, income and education) Lack of food (poverty related)
Regimen factors Pill burden, Side effects
Health care related factors Interaction with health personnel, Challenges of DOT
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Interaction with health personnel
The majority of patients in the study were happy about
the way health professionals received and treated them
at the health centers. Some said they were encouraged
to come for treatment because health professionals were
receiving them with a “good face”, and were encoura-
ging them to finish their treatment. A patient explained
the support she received from health professionals:
“They [health professionals] were very good to me. They
are like friends, did you not see? Since my head was not
good, they were giving me the drugs in a certain way, in
a bag, so that I know which drug to take when, they
translated it in Amharic for me. They gave me a watch,
they helped me a lot. They were like relatives. I have no
words to thank them. I am standing today because of
them. They told me what drugs to take at what time.”
(20 years old female patient)
When being asked about whether they received infor-
mation about TB, or about the drugs and potential side
effects, patients often replied that they did not get infor-
mation. A patient said:
“Someone might be kind, that is not because they
always give me drugs, they should also ask me what did
it cause on you, is it good, did it cause any harm, what
can we do for you? They have to say this. I come, they
see my card, I get my drugs, and I go. That’s all. Some-
one might be good naturally, but when I see from profes-
sion, it is less than I expected.” (male focus group
participant)
Few patients had asked health professionals at the TB
clinics the information they needed. Those who asked
questions tended to be more educated in general. For
most of the other patients, the information that they
had about TB and its treatment came from the commu-
nity, from other patients at the health centers and
mainly from the media. But many patients said that they
were given information regarding ART and its side
effects at the ART clinics. Health professionals said that
adherence counseling is critical for patients, and that
patients should be evaluated for their drug intake every
time they come for a visit. Some nevertheless said that
it had been difficult to do so, mainly because of time
constraints. A clinical nurse said:
“What we do is not enough. The counseling should be
done every time they come for treatment. Sometimes, we
just give them their drug and send them home. You do
not even know if they are taking the drugs the right
way.” (clinical nurse)
The challenges of DOT
The majority of patients said that DOT with daily
supervision of treatment for the first two months is a
very difficult task to accomplish. The initial phase of
treatment during which daily supervision is made was
the phase when many patients were ill and weak, and
for such patients, it meant that they often had to come
to the clinic accompanied by their families. This meant
that families were also bearing the burden of treatment.
In addition to physical weakness, transport costs were
also a problem for many patients who had financial
difficulties:
“I had to come every day for injections. I tell you the
truth, there was a time when I had to sell my jewellery:
my rings, my necklace, everything. I had to run here
without even eating breakfast.” (35 year-old female
patient)
DOT was particularly problematic for those patients
who had irregular jobs and who had to go looking for a
job on a daily basis. A 36 year-old daily laborer
explained his situation:
“I have to go in the morning. We stand at the round-
about and wait for someone to give us a job. If I don’t
go, someone else will take it. It will not stand and wait
for me.” (36 year old male patient)
All health professionals agreed that DOT with daily
supervision is a difficult task for most of their patients,
and in particular co-infected patients who needed to
attend the clinics for ART as well. Most believed that
DOT is too rigid, and some stated that something needs
to be done to modify the daily schedule into a better
schedule for patients. A medical doctor explains:
“Asking a person to come every day is a punishment.
We should change something; find a certain schedule, for
example weekly for the first month.” (medical doctor)
Timing of ART
Participants in this study had started ART at different
phases during TB treatment. Some were initiated on
ART in the intensive phase of TB treatment, some in
the continuation phase, and a few were already on ART
when they were started on treatment for TB. Patients
who had been told by health professionals that ART
would be delayed until the end of the intensive phase of
TB treatment were positive about this, since they had
fears and doubts about starting concomitant treatment
immediately. One group believed that their body would
“adapt” to the TB drugs with time, and it will make it
easier for them to tolerate the ART, hence allowing
them to follow both treatments properly. Three of the
patients who had defaulted treatment in this study said
that initiation of ART in the intensive phase of their
TB treatment had been too difficult, and that they were
unable to tolerate treatment. They said that delaying the
ART would have been better in their cases. A 36 years
old male defaulter who had discontinued both anti-TB
and ART drugs explained:
“It is better to take one drug and then the other drug.
Your stomach can tolerate it. Your body can tolerate it.
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Together, it is too much. That is why I stopped my
drugs.” (36 year-old male participant)
Stigma
Many patients believed that they were predisposed to
stigma because of TB. For many of these patients, that
was mainly due to the fact that people associated TB
with HIV. Many had seen other HIV patients suffering
from stigma and discrimination in their communities,
and feared that the same might happen to them. Some
shared their experiences, such as being pointed at in
their neighborhoods, neighbors gossiping about their ill-
ness behind their backs and exclusion from social
events. Some patients said the stigma was directly
related to the TB because they were believed to be
infectious. These actual experiences and anticipations of
stigma resulted in many patients hiding their diagnosis
of TB or only disclosing it to selected people, mostly
close families. A male focus group participant said:
“Before, I knew a lot of people with TB who did not
have HIV. But now, if you say you have TB, people will
take it to HIV. Me, even when I take these TB drugs, I
don’t tell to anyone.” (male focus group participant)
Fear of stigma not only lead to such patients not dis-
closing their illnesses but also made seeking TB treat-
ment in their catchments areas difficult as mentioned
earlier, for fear of being identified by neighbors:
“I don’t want neighbors to see me here [at the TB
clinic]. One day, I saw this girl from my neighborhood
here; I was sitting outside and waiting. I wished the
earth would open and swallow me. I know she would
spread the gossip. I tried to hide behind the man sitting
next to me. I don’t think she saw me.” (36 years old male
patient)
This fear was confirmed by many health professionals
who explained that they have faced difficulties with
patients who do not want to receive treatment in the
health centers located in their vicinity, for fear of being
identified by neighbors.
Social support
Social support was found to be crucial for patients’
treatment. Some patients had been seriously ill when
treatment was initiated and needed someone to accom-
pany them for treatment. In addition, families provided
food and transportation money since some patients had
no income and others had to stop working for some
time. Families were also a source of encouragement and
comfort for those patients who had lost hope.
“My family members supported me a lot. They encour-
aged me. After the TB, when they found the HIV, I
wanted to die. I did not want to live. But my families,
especially my brothers and sisters, they said: you are not
the only one. Look, many people have this. It is because
of them that I am alive today.” (female focus group
participant)
Some health professionals also noted that patients
who had family support and come to the clinics accom-
panied are usually those who successfully complete their
treatment.
Discussion
Our findings suggest that an interplay of factors is
involved in patients’ decision- making about use of con-
comitant treatment for TB and HIV. For the individual
patient, barriers act against a set of facilitating factors,
and the final decision about treatment depends on which
factors predominate. Although some of the factors are
related to poverty, and are more difficult to tackle, other
factors are liable to improvement through intervention.
Factors associated with adherence we have identified in
this study have previously been described in the literature
on adherence to TB treatment in different contexts.
These include side effects, rigidity of DOT, social support
and interaction with health personnel [12,16-23]. Other
factors appear to be more specific for patients who use
concomitant treatment for TB and HIV, such as beliefs
about concomitant illness and the experience of stigma.
Our focus in this study was adherence to TB treatment
in co-infected patients on concomitant treatment for TB
and HIV. Adherence to treatment of one illness was
found to affect adherence to the treatment of the other
illness: among the defaulters, one patient was found who
gave up TB treatment and continued ART after weighing
in benefits and costs associated with disease severity; and
other patients had decided to discontinue both
treatments.
TB as a curable condition
Patients’ belief that TB was a curable illness appeared to
be a motivating factor for adherence. Although some
authors had raised concern about the possibility of the
relation between TB and HIV enhancing the questioning
of the curability of TB [29], patients did not convey
such views in our study. Studies have shown that belief
in the efficacy of treatment facilitates adherence to TB
treatment [11,27,30]; while other studies describe how
patients’ adherence was adversely affected by belief that
TB is incurable or the treatment inefficient, or that
alternative treatment such as traditional medicine is bet-
ter [11,27,29-31]. Our findings suggest that informing
patients explicitly that TB is a curable disease might
motivate them for treatment.
Adherence counseling and information
Pill burden and side effects were major challenges to
concomitant treatment. The adverse impacts of pill bur-
den on adherence to treatment have previously been
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documented [8,15,32,33] and so have those of both per-
ceived and experienced side effects [11,18,34-38]. The
situation is further aggravated if health professionals do
not warn patients about side-effects. Our findings
suggest that adherence counseling might facilitate
adherence. TB and HIV clinics should work in colla-
boration to provide patients with uniform and complete
information. Patients should be well informed about co-
infection and concomitant treatment. Side effects, pill
burden and timing of ART in the course of TB treat-
ment should be thoroughly addressed. Beliefs related to
amount and quality of food that needs to be consumed
should be addressed. The importance of social support
for adherence to treatment should also be discussed
with patients.
Timing of ART
The national recommendation for the initiation of ART
in patients on anti-TB is to start patients with CD4 of
<200 on ART as soon as TB treatment is tolerated
(usually between 2 and 8 weeks); for those with a CD4
count between 200 and 350, ART is to be initiated once
the intensive phase of anti-TB is completed. ART is
deferred for those with CD4 greater than 350.Those
already on ART would continue their treatment [39].
We found that improper timing of ART treatment
after initiation of TB treatment could be a potential bar-
rier to patients’ adherence. Health personnel should dis-
cuss the timing of ART with the individual patient, in
order to ensure adherence to both treatments. Experts’
concern about adherence when multiple medications are
started at the same time has been used in determining
timing of ART during TB treatment in some guidelines
[5], and not actual evidences from studies, and this
needs to be further explored. In addition, patients
started on ART drugs early in their TB treatment can
also be predisposed to Immune Reconstitution Inflam-
matory Syndrome, presenting as transient worsening or
appearance of new signs and symptoms of TB [40]; this
and other clinical risks such as risk of mortality thus
need to be taken into consideration when deciding the
timing of ART treatment.
Stigma
Stigma is a potential barrier to treatment because it
makes patients reluctant to attend treatment in clinics
located in their neighborhoods and leads to non-disclo-
sure of illness. Disclosure can play a positive role because
it can help the patient mobilize social support thereby
facilitating adherence; and is also important for public
health reasons such as avoidance of further infection
transmission. But health professionals should be aware of
the negative impacts of self-disclosure in social environ-
ments where disease related stigma is widespread. In a
situation where consequences of disclosure are uncertain,
it may be rational for a patient not to disclose or to have
very selective disclosure. Studies have highlighted the
negative impacts of HIV-related stigma on TB treatment
in co-infected patients. A study from Thailand showed
that although both TB and HIV were stigmatized, more
stigma was attached to HIV, and that patients got delayed
in seeking treatment or defaulted from treatment of TB
when they suspected they have HIV and feared for it to
be detected [41]. A study from Nigeria showed that one
of the reasons for default in TB patients with HIV was
relocation secondary to HIV related stigma and discrimi-
nation [42]. There is a need to address both TB and HIV
related stigma in the local context, including through
information and communication using different channels.
The burden of treatment
DOT was found to be particularly challenging for this
group of patients, because of physical demands and eco-
nomic constraints; and because further attendances at
the clinic for ART were required. The literature had
previously documented the adverse impacts of DOT on
adherence to treatment [21,23]. A review of trials com-
paring DOT with self supervision of treatment showed
that there was no difference in treatment completion
between the two groups, as well as between patients
supervised by different groups of individuals (health pro-
fessional, lay health worker, family/community member)
[43]. Looking for alternative sources of supervision such
as community based supervision is necessary and
encouraging results have already been obtained in a
community based DOTS program in the Oromia Region
in Ethiopia [2].
Food
Our results suggest that providing early support in
terms of food and financial assistance to at least cover
transportation costs for patients with financial difficul-
ties might facilitate treatment. A number of NGOs
are already in place providing such supports for HIV
patients and their efforts should be encouraged and
strengthened. Health workers in the treatment facilities
could recommend to these NGOs that HIV patients
receiving concomitant TB and HIV treatment be given
special attention.
Methodological considerations
This study is based on interviews with a total of
29 patients and nine health professionals, and is limited
to one geographical area. But we think that our results
reflect diversity in views and experiences; we also trian-
gulated data sources in order to strengthen the validity
of our results. We thus believe our study can provide
valuable insights into the experiences of TB medication
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intake among co-infected patients on concomitant treat-
ment in other settings. In addition, there is a need to
conduct quantitative studies to further explore the mat-
ter and obtain generalizable results; and we believe the
findings of this study will be of paramount importance
for such studies.
Conclusion
Health professionals and policy makers should be aware
of factors influencing TB treatment in TB/HIV co-
infected patients on concomitant treatment for TB and
HIV. Our findings suggest that provision of food and
minimal financial support might facilitate adherence.
Counseling might also facilitate adherence, in particular
for those who start ART in the early phases of TB treat-
ment, and beliefs related to side-effects and pill burden
should be addressed. Information to the public may
reduce TB and HIV related stigma.
Conducting intervention studies addressing these dif-
ferent dimensions and documenting the impacts on
adherence is recommended.
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